Companies
Cullinan reports six-month median PFS gain for zipalertinib combination in Phase 3 REZILIENT3
Zipalertinib plus chemotherapy improved PFS and response rates in first-line EGFR exon 20 insertion NSCLC. Overall survival remains immature; Grade ≥3 AEs were more frequent with the combination.